Top Markets
#1 EXOD EXOD +56.80%
#2 MowCat MowCat +48.18%
#3 CoW Protocol CoW Protocol +44.40%
#4 Glidr Glidr +36.87%
#5 Humanity Humanity +26.78%
#6 Walrus Walrus +24.24%
#7 Codatta Codatta +19.91%
#8 Enso Enso +18.69%
#9 Collector Crypt Collector Crypt +14.14%
#10 The Black Bull The Black Bull +13.35%
Coin of the day
EXOD EXOD
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Carmell Therapeutics Corporation Carmell Therapeutics Corporation

Carmell Therapeutics Corporation

CTCX
Rang in Aktien #36666
Carmell Therapeutics Corporation (CTCX) specializes in the creation of... Carmell Therapeutics Corporation (CTCX) specializes in the creation of plasma-based bioactive materials (PBMs) aimed at catalyzing tissue regeneration and repair following injury, illness, or the effects of aging. Their flagship product, CT-101, is a versatile accelerant with a dual focus. For orthopedic and dental applications, it's designed to enhance bone healing in cases such as tibia fractures, foot and ankle fusions, spinal fusions, and also serves as a dental bone graft substitute and bone void filler. Furthermore, CT-101 acts as a tissue healing accelerant, addressing conditions like androgenetic alopecia (pattern baldness) and persistent chronic wounds. Established in 2008, the company operates from its headquarters in Pittsburgh, Pennsylvania.
Aktienkurs
$0.117
Zuletzt synchronisiert: 2025-04-04
Marktkapitalisierung
$2.45M
Veränderung (1 Tag)
-13.59%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Carmell Therapeutics Corporation (CTCX)

Kategorie

Healthcare
P/B-Verhältnis für Carmell Therapeutics Corporation (CTCX)
P/B-Verhältnis zum August 2026 TTM: -0.06
Laut den neuesten Finanzberichten und dem Aktienkurs von Carmell Therapeutics Corporation beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) -0.06. Am Ende des Jahres 2023 lag das P/B-Verhältnis bei 95.93.
P/B-Verlauf für Carmell Therapeutics Corporation von 2021 bis 2026
P/B-Verhältnis zum Jahresende
Jahr P/B-Verhältnis ändert
2026 (TTM) -0.06 -99.85%
2024 -37.13 -138.70%
2023 95.93 -161.62%
2022 -155.68 -19.29%
2021 -192.90 0.00%
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/B-Verhältnis P/B-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -11,404.63%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -11,225.31%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.4612 -6,269.70%
BE